Day One Biopharmaceuticals, Inc.

NasdaqGS:DAWN 주식 보고서

시가총액: US$1.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Day One Biopharmaceuticals 관리

관리 기준 확인 3/4

Day One Biopharmaceuticals' CEO는 Jeremy Bender, Sep2020 에 임명되었습니다 의 임기는 3.75 년입니다. 총 연간 보상은 $ 6.91M, 9.4% 로 구성됩니다. 9.4% 급여 및 90.6% 보너스(회사 주식 및 옵션 포함). 는 $ 22.74M 가치에 해당하는 회사 주식의 1.94% 직접 소유합니다. 22.74M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.3 년입니다.

주요 정보

Jeremy Bender

최고 경영자

US$6.9m

총 보상

CEO 급여 비율9.4%
CEO 임기3.8yrs
CEO 소유권1.9%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간3.3yrs

최근 관리 업데이트

Recent updates

Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair

Apr 24

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Mar 18
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Feb 01

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Dec 04
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

Jun 19
We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation

Nov 22
Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead

Sep 04

Day One Biopharmaceuticals GAAP EPS of -$0.60

Aug 04

Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price

Jun 18
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price

Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case

Jun 15

We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

Apr 29
We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate

An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued

Jan 14
An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Dec 10
Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Aug 27
Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans

Day One Biopharma draws bullish calls as quiet period ends

Jun 21

CEO 보상 분석

Jeremy Bender 의 보수는 Day One Biopharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$209m

Dec 31 2023US$7mUS$647k

-US$189m

Sep 30 2023n/an/a

-US$175m

Jun 30 2023n/an/a

-US$166m

Mar 31 2023n/an/a

-US$157m

Dec 31 2022US$5mUS$610k

-US$142m

Sep 30 2022n/an/a

-US$124m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$183m

Dec 31 2021US$20mUS$523k

-US$171m

Sep 30 2021n/an/a

-US$183m

Jun 30 2021n/an/a

-US$167m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$3mUS$142k

-US$41m

보상 대 시장: Jeremy 의 총 보상 ($USD 6.91M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.66M ).

보상과 수익: 회사가 수익성이 없는 동안 Jeremy 의 보상이 증가했습니다.


CEO

Jeremy Bender (53 yo)

3.8yrs

테뉴어

US$6,913,959

보상

Dr. Jeremy Bender, Ph D., M.B.A. serves as Chief Executive Officer, President and Director of Day One Biopharmaceuticals, Inc. since September 2020. He serves as President, Chief Executive Officer and Dire...


리더십 팀

이름위치테뉴어보상소유권
Jeremy Bender
CEO, President & Director3.8yrsUS$6.91m1.94%
$ 23.4m
Samuel Blackman
Co-Founder and Head of R&D6.5yrsUS$2.49m2.45%
$ 29.5m
Charles York
COO, CFO & Secretary3.4yrsUS$3.55m0.26%
$ 3.1m
Adam Dubow
General Counsel and Chief Compliance Officer1.8yrsUS$2.77m0.025%
$ 299.5k
Mike Preigh
Chief of Technology Operationsno data데이터 없음데이터 없음
Jaa Roberson
Chief People Officer2.8yrs데이터 없음데이터 없음
Davy Chiodin
Chief Development Officerno data데이터 없음데이터 없음
Lauren Merendino
Chief Commercial Officer1.5yrs데이터 없음데이터 없음
Elly Barry
Chief Medical Officerless than a year데이터 없음데이터 없음

2.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: DAWN 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Jeremy Bender
CEO, President & Director3.8yrsUS$6.91m1.94%
$ 23.4m
John Josey
Independent Director3.8yrsUS$350.75k0.083%
$ 996.1k
David Grayzel
Board Observerno data데이터 없음데이터 없음
Garry Nicholson
Chairman of the Board & Lead Independent Director1.8yrsUS$383.38k0%
$ 0
Daniel Curran
Board Observerno data데이터 없음데이터 없음
William Grossman
Independent Directorless than a year데이터 없음0%
$ 0
Scott Garland
Independent Director2.9yrsUS$342.88k0%
$ 0
Michael Gladstone
Independent Director4.6yrsUS$342.88k0%
$ 0
Sona Ramasastry
Independent Director3.3yrsUS$351.75k0.046%
$ 557.9k
Natalie Holles
Independent Director3.4yrsUS$352.50k0.066%
$ 789.7k
Habib Dable
Independent Directorless than a year데이터 없음0%
$ 0

3.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: DAWN 의 이사회경험(평균 재직 기간 3.3 년)으로 간주됩니다.